These novel drug approvals — meaning new products never before approved or marketed in the U.S. — and drugs approved in new settings included treatments for diseases and conditions such as COVID-19; HIV; smallpox; influenza; neurological conditions; heart, blood, kidney and endocrine diseases; and different cancers.
Here are four other things to know from the FDA’s Center for Drug Evaluation and Research report:
1. 2022 saw the 40th FDA-approved biosimilar.
2. Fifty-four percent of the novel drug approvals were for rare diseases, including a rare cancer that begins in the eye.
3. Twenty-five of the 37 novel approvals, or 68 percent, were first approved in the U.S.
4. Fifty-four percent were first-in-class drugs, meaning they had “mechanisms of action different from those of existing therapies.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
